ウルトラマコ

ウルトラマコ

海洋性脂質と卵黄レシチン（コリン）を配合したサプリメントです。団塊の人々の健康保持を考えた商品です。

レシチンとは

レシチンは、リン脂質（脂質の一種）です。 天然のレシチンの供給源としては卵黄、大豆等がしられています。人体を構成しているリン脂質により近い、卵黄リン脂質（卵黄レシチン・コリン含油）は人体への吸収も非常に優れており、健康食品素材として注目されています。

学術論文

1. Inhibition of Tyrosine Phosphorylation of Vascular Endothelial Growth Factor Receptors in Human Umbilical Vein Endothelial Cells: A Potent Anti-Angiogenic Lipid-Rich Extract from Shark. Journal of Medicinal Food 10(4) 2007, L Yuan, I Ahn, and P F. Davis.
2. Inhibition of Pro-Angiogenic Factors by a Lipid-Rich Shark Extract. Journal of Medicinal Food 9(3) 2006, 300-306. L Yuan, M Yoshida, and P F. Davis.
3. An Ethanolic extract from a shark having potent anti-angiogenic activity: its anti-angiogenic mechanism and clinical application. 2006 Angiogenesis Research & Therapeutics. I Ahn, S Grekin, S Verral and J Croft.
4. Shark Lipids for Treatment of Malignant Diseases. 2005 Annual Meeting of Korean Society of Cancer Prevention. S Furukawa.
5. Inhibition of Cancer Growth and Metastases by Preparations Based on Shark Oil. 2005 Annual Meeting of Korean Society of Cancer Prevention. P F Davis.
6. A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells. British Journal of Cancer (2005) 92, 328-333. M P Barr, A M Byrne, A M Duffy, C M Condron, M Devocelle, P Harriott, D J Bouchier-Hayes and J H Harmey.
7. The effects of functional foods, such as Agaricus, Pleurotus cornucopiae (Paulet) Rolland var. citrinopileatus (Sing.) Ohira., Hericium erinaceum, Arabinoxylan, Shark cartilage and Shark extracted lipid on growth of implanted Mouse LM8 Dunn osteosarcoma. The 137th meeting of the Japanese Society of Veterinary Science. N Kido, S Takagi, K Shimada, T Kadozawa, M Okumura and T Fujinaga.
8. A novel, potent, orally-active natural anti-angiogenic preparation, Asia Pacific Anti-Aging Conference 2004, P F Davis, N S Greenhill, A D. MacKenzie, G C Slim, F Shirota.
9. VEGF Receptor Signaling in Tumor Angiogenesis. The Oncologist 2000, 5:3-10. Gerald McMahon.
10. Selective Inhibition of Vascular Endothelial Growth Factor (VEGF) Receptor 2 (KDR/Flk-1) Activity by a Monoclonal Anti-VEGF Antibody Blocks Tumor Growth in Mice. Cancer Research 60, 5117-5124, September 15, 2000, R A. Brekken, J P. Overholser, V A. Stastny, J Waltenberger, J D. Minna, and P E. Thorpe.
11. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney International, Vol. 56 (1999) 794-814. N Ferrara.
12. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. Journal of Cell Science 111, 1853-1865 (1998). S Esser, M G Lampugnani, M Corada, E Dejana and W Risau.
13. Inhibition of Vascular Endothelial Growth Factor (VEGF)-induced Endothelial Cell Proliferation by a Peptide Corresponding to the Exon 7-Encoded Domain of VEGF. J. Biol. Chem. 1997, 272:31582-31588. S Soker, S Gollamudi-Payne, H Fidder, H Charmahelli, and M Klagsbrun.
14. Vascular Endothelial Growth Factor Stimulates Tyrosine Phosphorylation and Recruitment to New Focal Adhesions of Focal Adhesion Kinase and Paxillin in Endothelial Cells. J. Biol. Chem. 1997, 272:15442-15451. H Abedi and I Zachary.
15. Expression of Vascular Endothelial Growth Factor, Its Receptor, and Other Angiogenic Factors in Human Breast Cancer. Cancer Research 56, 2013-2016 1996. H Yoshiji, D E. Gomez, M Shibuya, and U P. Thorgeirsson.
16. Different Signal TransductionP roperties of KDR and Fltl, Two Receptors for Vascular Endothelial Growth Factor. The Journal of Biological Chemistry 1994 Vol. 269, No. 43. J Waltenberger, L Claesson-Welsh, A Siegbahn, M Shibuya, and Carl-Henrik Heldin.